There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taro Pharmaceutical (TARO – Research Report) and Aurinia Pharmaceuticals (AUPH – Research Report) with bullish sentiments.
Taro Pharmaceutical (TARO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Taro Pharmaceutical, with a price target of $35.00. The company’s shares closed last Tuesday at $30.85, close to its 52-week low of $27.50.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Taro Pharmaceutical with a $35.00 average price target.
See the top stocks recommended by analysts >>
Aurinia Pharmaceuticals (AUPH)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Tuesday at $8.21.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $11.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
